An underground economy for unlicensed weight-loss drugs is being driven by social media fitness personalities and sellers on communication apps, according to new investigations.
Investigational Drug Acquiring Traction Online
Retatrutide, which remains in clinical trials, is being advertised by social media influencers for its supposed weight-reducing properties. Viewers are urged to message these profiles privately for source information, while also obtaining discount codes.
Active Commerce on Messaging Platforms
Additionally, a flourishing market exists on messaging services, where communities with thousands of members share “before and after” images, injection guides and claims of rapid British shipping. Vendors promote the substance there before directing customers to other platforms for purchases.
Understanding The Experimental Drug
Retatrutide is an experimental injection developed by US drugmaker Eli Lilly. The drug affects three gut hormones – glucagon-like peptide-1, GIP and pancreatic hormone. Early trials indicate it could assist patients reduce up to a quarter of their total weight. Nicknamed the “triple G”, the substance is being promoted online as the successor to Ozempic.
Medical Experts Voice Concerns
Nevertheless, physicians and pharmacists have cautions that the distribution of what is still an unlicensed drug in the United Kingdom is a cause for concern and could result in individuals administering products of unknown origin.
Several professionals said the popularity for retatrutide could be linked to the increasing cost of approved slimming treatments such as Mounjaro.
Legal Status and Enforcement
Selling the unapproved drug on social media or messaging apps is prohibited in the United Kingdom, as it is an unlicensed medication that cannot be marketed or supplied for personal consumption under the British medical regulations.
Some content creators try to sidestep the regulations by referring to the substance as a “research chemical” or citing it as “not for human consumption”. The substance is not a restricted drug, but advertising and distribution can still breach pharmaceutical, advertising, and consumer regulations, risking penalties, legal action or imprisonment.
Service Response and Content Elimination
According to TikTok, the platform has taken down violative content and banned related hashtags and search suggestions. The company stated it was dedicated to maintaining the platform safe and investing in strengthening enforcement strategies.
Online Marketplace Activities
Investigations also discovered communities with up to 9,000 participants selling retatrutide using Telegram's built-in discovery tool, which operates like a online catalog. Typing “retatrutide” instantly displays groups with thousands of users, filled with images of slimming results, glowing testimonials and step-by-step guides for mixing or injecting at residence.
After moments of entering one group, a vendor shared contact information, where most transactions occur. The vendor provided an guidebook and guaranteed delivery within two days. When asked whether the product was authentic, one seller said: “You can’t be sure.” Another provided a image of a supposed laboratory certificate. None inquired about weight, health issues or past usage.
Product Details and Pricing
Inside these groups, posts display black plastic packages with postal service labels, stating to contain new batches. One message read: “It took eight of us to load them this morning.”
Customers can select between powder vials, mixed at home with sterile water, or pre-filled injectors usually priced at 160 pounds for 20mg. When asked how much time a pen should last, vendors give contradictory answers ranging from a several days to “depends on your body”.
Platform Oversight and Security Actions
A spokesperson for Telegram said it actively monitored dangerous content on its platform including content that promoted the “misuse of controlled medications”. The organization added that it eliminated “millions of pieces of harmful content each day”.
Healthcare Expert Cautions
“Individuals are administering materials they cannot confirm. Even if the research behind retatrutide is sound, these online products may not include what they advertise,” said a pharmacy expert, the head of pharmacy at a pharmacy service.
A medical professional of Asda Online Doctor linked the surge in interest to current price rises for approved slimming drugs such as Mounjaro. “With prices increasing, patients are turning to social media. But fake treatments are highly risky. You can’t be certain what’s contained or whether the environment they were produced in was sterile,” she explained.
Her staff has previously seen patients harmed by personal administration from unverified suppliers. “We understand the frustration, but purchasing from messaging apps or communication platforms is taking chances with your well-being,” said Wyllie. “These substances could be impure or improperly measured.”
Manufacturer Statement
A spokesperson from Eli Lilly said retatrutide was in third stage clinical trials and had not been reviewed or approved by any government authority anywhere in the world. “Consequently at this time no one can sell [it] for human use,” they said, adding that any item “falsely representing itself as a Lilly experimental product not yet approved … may expose patients to possibly serious health risks”.
